Who we are
Welcome to CortexBio where science, innovation, and patient impact converge. Explore how integrative vision and cross-disciplinary collaboration are transforming the future of metabolic health. Discover our mission, latest breakthroughs, and how you can get involved.
I am Dima Martini-Drew MD, a seasoned leader in rare and metabolic diseases, whose journey spans over 25 years of transformative research, clinical innovation, and patient advocacy.
Expertise
Professional Summary
Dima Martini-Drew MD
As a seasoned biotechnology executive, I bring over 25 years of transformative leadership experience in drug discovery and development, with a unique and unwavering focus on rare genetic and metabolic diseases. My track record is marked by the successful management and driving of strategic initiatives that have led to groundbreaking therapies. My expertise in fatal rare and metabolic diseases, particularly in developing modalities from discovery onwards, has ignited my passion to apply my strategic leadership and global collaboration skills to lead innovative scientific programs.
Key Strengths and Expertise
Proven track record in Strategic Leadership and Vision
Effective Cross-Functional Team Management
Successful Drug Discovery and Development experience
Specialised in Metabolic and Rare Diseases
Creative and Innovative Therapeutic Strategies
Strong Global Collaboration and Communication skills
Effective Change Management and Adaptability
Business-savvy mindset with a focus on Business Development and Market Access Strategies
Multilingual abilities and experience in external relations.
Key Career Achievements
Led the development of small molecule mitochondrial biologics targeting the blood-brain barrier, demonstrating my expertise in neurology and rare diseases.
Directed the launch of four enzyme replacement therapy programs for rare diseases, expanding patient access and demonstrating leadership in clinical development from early-stage to market launch.
Pioneered high-risk population testing programs for Fabry Disease, revolutionising the understanding of X-linked genetic diseases and showcasing my expertise in genetic disorders.
Developed novel identification tools leading to the treatment of the youngest Pompe Disease patient, resulting in new treatment guidelines and impacting clinical practice.
Led medical integration teams during major pharmaceutical acquisitions, showing change management skills and the ability to align medical strategies across organisations.
Established thought leadership in rare diseases through public speaking and patient advocacy, displaying the ability to represent the company externally and influence stakeholders.
Successfully led cross-functional teams in developing and implementing clinical development strategies for rare neurological disorders, resulting in multiple successful product launches.
Positions in Big Pharma
Astellas
Early-Stage Medical Strategy Lead, Mitochondria and Rare Diseases
Abbott
Strategic Medical Director
Genzyme Corporation
Global Medical Director of Nephrology, Endocrinology and Rare Diseases
Professional Affiliations
Founding member of multiple programs within the Critical Path Institure Rare and Orphan Diseases.
Vision
To reveal the hidden architecture of human metabolism and transform it from a source of vulnerability into a source of opportunity uniting the worlds of rare diseases and aging.
Our vision is not merely to treat, but to illuminate, connect, and empower as a foundation for longer, healthier and more meaningful lives.
Mission
To relentlessly pursue the intersections between disciplines, age and rarity by pioneering integrative science and championing the lived experience of every patient.
Our mission is to dismantle barriers; scientific, regulatory and societal so that innovation flows from bench to bedside driven by the conviction that the answers to our most complex health challenges lie not in isolation, but in the spaces where ideas and people converge.
How can we help
Advocacy
CortexBio's advocacy services bridge the crucial gap between pharmaceutical and biotech companies with patient communities, creating meaningful partnerships that drive innovation and improve outcomes. Our approach extends beyond traditional engagement to establish authentic collaborations that amplify patient voices throughout the entire drug development lifecycle.
Clinical Development Readiness
CortexBio offers strategic guidance and hands-on support to optimise your clinical development journey, leveraging specialised expertise in rare and metabolic diseases. We help companies navigate the complex landscape of clinical development, from early planning through execution and regulatory submission.
Educational Activities
CortexBio delivers specialised educational programs to enhance the understanding of rare diseases, metabolic disorders, and their interconnections. Our scholastic activities are designed to empower diverse audiences, including healthcare professionals, patients, researchers, and industry stakeholders.
Patient Focused Drug Development
CortexBio helps pharmaceutical and biotech companies implement effective patient-focused drug development (PFDD) strategies that meaningfully incorporate patient experiences throughout the therapeutic development lifecycle. Our approach aligns with evolving regulatory guidance while delivering authentic patient insights that enhance product development and innovation.
Longevity and Age-Related Disease Consultancy
CortexBio offers specialised consulting services that focus on the intersection of ageing biology and disease mechanisms, enabling clients to navigate this rapidly evolving field effectively. We translate cutting-edge longevity science into practical applications for therapeutic development, biomarker discovery, and clinical trial design.
Rare Disease Consultancy
CortexBio delivers specialised consulting services for organisations developing therapies for rare and ultra-rare diseases, providing strategic guidance throughout the development journey. Our approach combines scientific expertise with practical experience navigating the unique challenges of rare disease drug development.
Resources